IBIO
iBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.76
−0.81%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-44.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 15, 2026 | Kropotova Alexandra · director | A-Award | 38,000 | $0.78 |
| Oct 15, 2026 | Parada Antonio Bernardino Guimaraes · director | A-Award | 38,000 | $0.78 |
| Oct 15, 2026 | Stoner Elizabeth · director | A-Award | 38,000 | $0.78 |
| Oct 15, 2026 | Sender Gary · director | A-Award | 38,000 | $0.78 |
| Oct 15, 2026 | Arkowitz David · director | A-Award | 38,000 | $0.78 |
| Oct 15, 2026 | Clark William D · director | A-Award | 38,000 | $0.78 |
| Aug 4, 2026 | Carr Molly · officer: Chief Medical Officer | A-Award | 430,000 | $1.40 |
| May 19, 2026 | Stoner Elizabeth · director | A-Award | 60,000 | $1.42 |
| Mar 27, 2026 | Banjak Marc · officer: Chief Legal Officer | Purchase | 12,500 | $1.64 |
| Mar 27, 2026 | Banjak Marc · officer: Chief Legal Officer | Purchase | 1,434 | $1.76 |
| Mar 23, 2026 | Duran Felipe · officer: Chief Financial Officer | Purchase | 24,835 | $2.02 |
| Mar 23, 2026 | Brenner Martin · director, officer: See Remarks | Purchase | 12,336 | $2.02 |
| Jan 30, 2026 | Banjak Marc · officer: Chief Legal Officer | A-Award | 146,000 | $2.23 |
| Jan 30, 2026 | Brenner Martin · director, officer: See Remarks | A-Award | 479,000 | $2.23 |
| Jan 30, 2026 | Duran Felipe · officer: Chief Financial Officer | A-Award | 179,000 | $2.23 |
| Nov 24, 2025 | Sender Gary · director | A-Award | 13,500 | $1.00 |
| Nov 24, 2025 | Clark William D · director | A-Award | 13,500 | $1.00 |
| Nov 24, 2025 | Schimmelpennink Evert B. · director | A-Award | 13,500 | $1.00 |
| Nov 24, 2025 | Kropotova Alexandra · director | A-Award | 13,500 | $1.00 |
| Nov 24, 2025 | Parada Antonio Bernardino Guimaraes · director | A-Award | 13,500 | $1.00 |
| Nov 24, 2025 | Arkowitz David · director | A-Award | 13,500 | $1.00 |
| Oct 22, 2025 | Duran Felipe · officer: Chief Financial Officer | A-Award | 75,000 | $0.89 |
| Oct 22, 2025 | Banjak Marc · officer: Chief Legal Officer | A-Award | 55,000 | $0.89 |
| Oct 22, 2025 | Brenner Martin · director, officer: See Remarks | A-Award | 180,000 | $0.89 |
| Feb 24, 2025 | Brenner Martin · director, officer: See Remarks | A-Award | 230,700 | $3.48 |
| Feb 24, 2025 | Duran Felipe · officer: Chief Financial Officer | A-Award | 84,700 | $3.48 |
| Feb 24, 2025 | Banjak Marc · officer: Chief Legal Officer | A-Award | 71,000 | $3.48 |
| Jan 13, 2025 | Arkowitz David · director | Purchase | 18,382 | $2.72 |
| Jan 13, 2025 | Clark William D · director | Purchase | 1,838 | $2.72 |
| Jan 13, 2025 | Parada Antonio Bernardino Guimaraes · director | Purchase | 183,823 | $2.72 |
Institutional positioning
13F filings over the trailing two quarters
New 32Increased 35Reduced 19Sold out 14
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Affinity Asset Advisors, LLC | Increased | 4,007,881 | Aug 13, 2026 |
| Cormorant Asset Management, LP | New Position | 3,570,000 | Aug 14, 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | Increased | 3,520,490 | Aug 13, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 3,107,200 | May 14, 2026 |
| Vestal Point Capital, LP | New Position | 2,600,000 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,098,151 | Aug 13, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 1,953,467 | May 15, 2026 |
| Frazier Life Sciences Management, L.P. | Unchanged | 1,953,467 | Aug 14, 2026 |
| Ensign Peak Advisors, Inc | New Position | 1,832,457 | Aug 14, 2026 |
| Woodline Partners LP | New Position | 1,776,547 | Aug 14, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 1,651,473 | Aug 14, 2026 |
| ECOR1 CAPITAL, LLC | Reduced | 1,583,000 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | New Position | 1,549,850 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 1,384,029 | Sep 2, 2026 |
| LOGOS GLOBAL MANAGEMENT LP | Reduced | 1,300,000 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 15, 2026